In the landmark Second International Study of Infarct Survival  trial, published in 1988, 17,187 suspected AMI patients were  treated with either streptokinase or aspirin, with both drugs, or with neither. The mortality rate in the combination group of this trial was 8%, compared with 13.2% in those patients given neither streptokinase nor aspirin [17] .